Skip to content
Grounds publishedDecided 14 Feb 2025
Contents

Singapore International Commercial Court

Novo Nordisk A/S v KBP Biosciences Pte Ltd and another and another matter

Feedback & support

[2025] SGHC(I) 3Case no. Originating Application No 3 of 2025 and Summons 11 of 20255 paragraphs

What happened, in plain English

There is no plain-English summary of this judgment yet.

Ask about this judgment

Laws this judgment relies on

Grounds of decision

Official text from eLitigation

  1. [2] The arbitration is to be administered by the International Chamber of Commerce (“ICC”) pursuant to the ICC Rules. While reference is also made in the arbitration clause to the ICC’s Emergency Arbitrator Rules, recourse to an Emergency Arbitrator thereunder is not available ex parte or without notice. The arbitration clause expressly extends to officers and directors of the parties, and thus includes Dr Huang. Dr Huang executed the APA on KBP’s behalf. Novo’s position is that Dr Huang is bound by the arbitration agreement.

  2. [5] I am satisfied that Novo has shown that it has a good arguable case against KBP for fraud under New York law, which governs the dispute. On the face of the APA, Novo obtained representations and warranties from KBP that it had “made available to [Novo] true, complete and accurate copies of … all material information … concerning the safety, efficacy, … or manufacturing quality and controls of any Compound or Product”. Arguably, KBP knowingly failed to disclose material information, including interim analyses of Phase 2 clinical trial results showing Ocedurenone’s inefficacy, and information concerning quality and compliance issues at a single test site that produced anomalous positive results. Likewise, Dr Huang arguably knew and participated in these misrepresentations. He was the founder, Executive Chairman and a 40% shareholder of KBP. There is a good arguable case that when Dr Huang executed the APA he did so conscious of the unfavourable data. There is evidence that he had seen that data, including internal analyses from March 2022. While the claim against Dr Huang would be tortious, Novo’s position is that it comes within the arbitration clause.

  3. [6] I am also satisfied that there is a real risk of dissipation. The expert analysis tendered by Novo identifies transfers totalling US$339.1m from KBP to its holding company around the time of closing, as well as a declaration of US$578.5m in dividends. Novo submits that the steps taken show an intention on Dr Huang’s part to remove assets from Novo’s reach in anticipation of a claim by Novo. There is no clear commercial rationale for these actions. A seller of assets is ordinarily free to do as it pleases with the proceeds of sale from such assets. However, evidence that the seller knowingly misrepresented the value of those assets and anticipates a claim by the buyer will call into question its motives in its dealings with those proceeds, where the effect of those dealings is such as to put the proceeds beyond the reach of the buyer. That is what the evidence here points to.

  4. [9] In addition, as the claimants rightly point out, no arbitral tribunal has been constituted yet. Further, under the ICC’s Emergency Arbitrator rules, an emergency arbitrator could not hear the application ex parte. Thus, any arbitral tribunal has no power or is unable for the time being to act effectively. It is precisely where such a gap in protections exists that the IAA’s grant of powers to the courts of Singapore is of use and relevance.

  5. [11] Novo has given to the court the usual undertakings, including an undertaking as to damages. I am satisfied that Novo is in a position to meet the undertaking as to damages, should it become necessary to enforce it.